QURE
USDuniQure N.V. Ordinary Shares
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$30.810
Haut
$32.490
Bas
$28.500
Volume
8.90M
Fondamentaux de l'Entreprise
Capitalisation Boursière
1.9B
Industrie
Biotechnologie
Pays
Netherlands
Statistiques de Trading
Volume Moyen
3.75M
Bourse
NMS
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (QURE)
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. ("uniQure" or the "Company") (NASDAQ:QURE). The investigation concerns whether the
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $38
Goldman Sachs analyst Salveen Richter maintains uniQure with a Neutral and lowers the price target from $56 to $38.
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $45
RBC Capital analyst Luca Issi maintains uniQure with a Outperform and lowers the price target from $65 to $45.
William Blair Downgrades uniQure to Market Perform
William Blair analyst Sami Corwin downgrades uniQure from Outperform to Market Perform.
HC Wainwright & Co. Maintains Buy on uniQure, Lowers Price Target to $70
HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure with a Buy and lowers the price target from $110 to $70.
Chardan Capital Maintains Buy on uniQure, Lowers Price Target to $53
Chardan Capital analyst Daniil Gataulin maintains uniQure with a Buy and lowers the price target from $76 to $53.
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.